Table IV.
Multivariate analysis of prognostic factors influencing OS and DFS.
| OS | DFS | |||||
|---|---|---|---|---|---|---|
| Factor | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Model 1 | ||||||
| Age, years (≥60 or <60) | 1.586 | 1.039–2.423 | 0.033 | |||
| Albumin (≥49.5 or <49.5 g/dl) | 3.037 | 1.528–6.033 | 0.003 | |||
| TNM stage (I–II or IIIA) | 1.602 | 1.019–2.517 | 0.041 | |||
| CO-NPF (≥2 or <2) | 2.177 | 1.420–3.337 | <0.001 | 1.904 | 1.210–3.020 | 0.006 |
| Model 2 | ||||||
| Age, years (≥60 or <60) | 1.814 | 1.196–2.752 | 0.005 | |||
| Albumin (≥49.5 or <49.5 g/dl) | 2.731 | 1.357–5.494 | 0.005 | |||
| TNM stage (I–II or IIIA) | 1.621 | 1.069–2.460 | 0.023 | 1.878 | 1.215–2.905 | 0.005 |
| NLR (≥2.16 or <2.16) | 1.782 | 1.176–2.700 | 0.006 | |||
| Model 3 | ||||||
| Age, years (≥60 or <60) | 1.738 | 1.142–2.643 | 0.010 | |||
| Albumin (≥49.5 or <49.5 g/dl) | 2.615 | 1.313–5.211 | 0.006 | |||
| TNM stage (I–II or IIIA) | 1.538 | 1.006–2.351 | 0.047 | 1.715 | 1.097–2.681 | 0.018 |
| PLR (≥145 or <145) | 2.005 | 1.294–3.106 | 0.002 | 1.609 | 1.004–2.577 | 0.048 |
| Model 4 | ||||||
| Age, years (≥60 or <60) | 1.956 | 1.284–2.980 | 0.002 | |||
| Albumin (≥49.5 or <49.5 g/dl) | 2.099 | 1.046–4.214 | 0.037 | |||
| TNM stage (I–II or IIIA) | 1.878 | 1.215–2.905 | 0.005 | |||
| PLT (≥289 or <289 ×109 cells/l) | 2.276 | 1.432–3.617 | 0.001 | |||
| Model 5 | ||||||
| Age, years (≥60 or <60) | 1.553 | 1.009–2.389 | 0.045 | |||
| Albumin (≥49.5 or <49.5 g/dl) | 2.437 | 1.224–4.852 | 0.011 | |||
| TNM stage (I–II or IIIA) | 1.716 | 1.131–2.604 | 0.011 | 1.871 | 1.209–2.894 | 0.005 |
| FBG (≥4 or <4 g/l) | 2.045 | 1.332–3.141 | 0.001 | 1.865 | 1.196–2.910 | 0.006 |
TNM, tumor-node-metastasis; HR, hazard ratio; CI, confidence interval; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PLT, platelet; FBG, fibrinogen; CO-NPF, combination of NLR, PLR, FBG and PLT; OS, overall survival; DFS, disease-free survival.